LBT automated AI assisted MRSA module testing results demonstrated no false positives, and in addition, detected an additional 3 MRSA positive samples not detected by human pathologists. Very immpressive results so far...see report for details.
2 Announcements from LBT today
Highlights from the first:
LBT TEAMS WITH GLOBAL CLINICAL DIAGNOSTIC COMPANY BECKMAN COULTER
•Three-year Agreement for marketing and lead generation services with Beckman Coulter
•EU focus with initial territories of Germany, U.K. and France –ability to extend to additional countries
•Beckman Coulter will promote the APAS®Independence in their suite of lab automation solutions
The second was to announce a trading halt in relation to an SPP, seel following link.
In relation to GMO11's straw, I think it is important to note that the time saving indicated in the poster was in relation to their specific lab which has only a throughput of 70 plates per day, which they classify as moderate volumes.
The poster then goes on to say that a high throughput lab (high volumes of plates) would benefit more in terms of efficiency. This is pretty standard for scientific instrumentation. I am not a microbiologist, but am very familiar with chemical testing which pioneered high throughput testing over the past 20 years. Automation greatly improved efficiencies in big commercial testing labs. In addition to that smaller university labs bought the instrumentation anyway because it was the latest thing, even though they did not particularly benefit from the efficiency gains in some cases.
The exact benefit in efficiency is not clear for a high-throughput lab that processes hundreds of plates a day, but I would imagine that it would be significant. Again I am not specifically familiar with the microbiology setting, but a high throughput technology could give a competetive advantage to a lab to expand testing numbers without increasing staff and getting improved accuracy. From my understanding the technicians time would be spent only preparing the plates. The analysis would then be conducted by the LBT device
PS: Strawman/Andrew it would be a good feature to directly reply to straws.
Disclosure: I do not hold LBT, at least not yet, was seriously considering with the ~15% pull back today, though while not profitable this stock still has the potential to go down in price.
LBT have sold their first automated pathology unit (Apas) It utilises AI to screen specimens and provides high accuracy results. LBT also have MRSA module pending FDA approval. See ASX report for details.
Reporting on the Johns Hopkins report. Positive, doesn't mention the fairly poor result of only a 10% saving on technician time.